# Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

> **NCT01217398** · PHASE2 · UNKNOWN · sponsor: **Institut Curie** · enrollment: 35 (estimated)

## Conditions studied

- Intraocular Melanoma

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** temozolomide
- **GENETIC:** polymorphism analysis
- **OTHER:** pharmacogenomic studies

## Key facts

- **NCT ID:** NCT01217398
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-10
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217398, "Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01217398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*